Small peripheral pulmonary adenocarcinoma: Morphologic and molecular update

Advances in Anatomic Pathology

Volumn 14, Issue 2, 2007, Pages 120-128

  Weydert, Jamie A ^a,b   Cohen, Michael B ^a  

^a UNIVERSITY OF IOWA   (United States)

^b 5239 RCP ^*  (United States)

Author keywords

Bronchioloalveolar carcinoma; Epidermal growth factor receptor; Nonsmall cell lung carcinoma; Surgical pathology; Tyrosine kinase inhibitor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ANGIOGENESIS; CANCER SURGERY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; EVOLUTION; GENE LOCUS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MORPHOLOGY; PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; STROMA; TUMOR GROWTH;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; GENE DOSAGE; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34247582963     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3180324519     Document Type: Review

References (65)

1. Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Ries LAG, Harkins D, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site 2006. Last accessed November 21, 2006.
3. Henschke CI, Yankelevitz DF, Libby DM, et al. International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355:1822-1824.
4. Martini N, Rusch VW, Bains MS, et al. Factors influencing ten-year survival in resected stages I to IIIa non-small cell lung cancer. J Thorac Cardiovasc Surg. 1999;117:32-36.
5. Naruke T, Goya T, Tsuchiya R, et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988;96:440-447.
6. Read WL, Page NC, Tierney RM, et al. The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer. 2004;45:137-142.
7. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology. 2003;226:756-761.
8. Mulshine JL, Glatstein E, Ruckdeschel JC. Treatment of non-small cell lung cancer (Review). J Clin Oncol. 1986;4:1704-1715.
9. Sakurai M, Shinkai T, Equchi K, et al. Prognostic factors in non-small cell lung cancer: multiregression analysis in the National Cancer Center Hospital, Japan. J Cancer Res Clin Oncol. 1987;113:563-566.
10. Travis WD, Brambilla E, Muller-Hermelink HK, et al. eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, France: IARC Press; 2004.
11. Shepherd FA, Rodriques Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353:123-132.
12. Herbst RS, Bunn PA Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2003;9:5813-5824.
13. Shimosato Y, Sobin LH, Spencer H, et al. eds. World Health Organization International Histological Classification of Tumours. Histological Typing of Lung Tumours. 2nd ed. Geneva: WHO; 1981.
14. Dorland's Illustrated Medical Dictionary. 28th ed. Philadelphia: WB Saunders Co.; 1994;915.
15. Zell JA, Ignatius Ou SH, Ziogas A, et al. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol. 2005;23:8396-8405.
16. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer. 1995;75:2844-2852.
17. Travis WD, Colby TV, Corrin B, et al. eds. World Health Organization International Classification of Tumours. Histological Typing of Lung and Pleural Tumours. 3rd ed. Germany: Springer Berlin; 1999.
18. Breathnach OS, Kwiatkowski DJ, Finkelstein DM, et al. Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease. J Thorac Cardiovasc Surg. 2001;121:42-47.
19. Rena O, Papalia E, Ruffini E, et al. Stage I pure bronchioloalveolar carcinoma: recurrences, survival, and comparison with adenocarcinoma of the lung. Eur J Cardiothorac Surg. 2003;23:409-414.
20. Volpino P, Andrea ND, Cangemi R, et al. Bronchioloalveolar carcinoma: clinical, radiographic, and pathological findings, Surgical results. J Cardiovasc Surg. 2001;42:261-267.
21. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
22. Yoshimi I, Ohshima A, Ajiki W, et al. A comparison of trends in the incidence rate of lung cancer by histological type in the Osaka Cancer Registry, Japan and in the Surveillance, Epidemiology and End Results Program, USA. Jpn J Clin Oncol. 2003;33:98-104.
23. Suzuki K, Yokose T, Yoshida J, et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg. 2000;69:893-897.
24. Eto T, Suzuki H, Honda A, et al. The changes of the stromal elastotic framework in the growth of peripheral lung adenocarcinomas. Cancer. 1996;77:646-656.
25. Maeshima AM, Niki T, Maeshima A, et al. Modified scar grade: a prognostic indicator in small peripheral lung adenocarcinoma. Cancer. 2002;95:2546-2554.
26. Shimosato Y, Suzuki A, Hashimoto T, et al. Prognostic implication of fibrotic focus (scar) in small peripheral lung cancers. Am J Surg Pathol. 1980;4:365-373.
27. Yamashiro K, Yasuda S, Nagase Ahirata T, et al. Prognostic significance of an interface pattern of central fibrosis and tumor cells in peripheral adenocarcinoma of the lung. Hum Pathol. 1995;26:67-73.
28. Yokose T, Suzuki K, Nagai K, et al. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer. 2000;29:179-188.
29. Terasaki H, Niki T, Matsuno Y, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 2003;27:937-951.
30. Sakurai H, Maeshima A, Watanabe S, et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol. 2004;28:198-206.
31. Ginsberg RJ, Rubinstein LV, Lung Cancer Study Group. Resection for T1 N0 non-small cell lung cancer. Ann Thorac Surg. 1995;60:615-623.
32. Miller DL, Rowland CM, Deschamps C, et al. Surgical treatment of non-small cell lung cancer 1 cm or less in diameter. Ann Thorac Surg. 2002;73:1545-1550.
33. Yamato Y, Tsuchida M, Watanabe T, et al. Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung. Ann Thorac Surg. 2001;71:971-974.
34. Watanabe S, Watanabe T, Arai K, et al. Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography. Ann Thorac Surg. 2002;73:1071-1075.
35. Veale D, Ashcroft T, Marsh C, et al. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer. 1987;55:513-516.
36. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839;Iressa) tablets. Clin Cancer Res. 2004;10:1212-1218.
37. Cohen MH, Johnson JR, Chen Y-F, et al. FDA drug approval summary: Erlotinib (Tarceva) tablets. Oncologist. 2005;10:461-466.
38. Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005;11:6414-6421.
39. Tsao M-S, Sakurada A, Cutz J-C, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144.
40. Shepard FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353:123-132.
41. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo controlled study in advanced non-small cell lung cancer. J Clin Oncol. 2006;24:5034-5042.
42. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (Iressa, ZD1839) in non-small cell lung cancer. Br J Cancer. 2004;91:208-212.
43. Cappuzzo F, Gregorc V, Rossi E, et al. Gefitinib in pretreated non-small cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol. 2003;21:2658-2663.
44. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small cell lung cancer. Ann Oncol. 2004;15:28-32.
45. Meert AP, Martin B, Delmonte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J. 2002;20:975-981.
46. Suzuki S, Dobashi Y, Sakurai H, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. Cancer. 2005;103:1265-1273.
47. Hirsh FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807.
48. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small cell lung cancer. J Clin Oncol. 2005;23:6829-6837.
49. Dacic S, Flanagan M, Cieply K, et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Pathol. 2006;125:860-865.
50. Hirsch FR, McCoy J, Cappuzzo F, et al. FISH and immunohistochemistry (IHC) can be used to select NSCLC patients who will not benefit from gefitinib treatment. Lung Cancer. 2005;49(suppl 3):S38.
51. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
52. Han S-W, Kim T-Y, Jeon YK, et al. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and akt phosphorylation. Clin Cancer Res. 2006;12:2538-2544.
53. Eberhand DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900-5909.
54. Blons H, Cote J-F, Le Corre D, et al. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation. Am J Surg Pathol. 2006;30:1309-1315.
55. Han S-W, Kim T-Y, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493-2501.
56. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations in the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;232:2513-2520.
57. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857-865.
58. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339-346.
59. Ho C, Murray N, Laskin J, et al. Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell lung carcinoma of the lung in North America. Lung Cancer. 2005;49:225-231.
60. Zheng Z, Bepler G, Cantor A, et al. Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early stage non-small cell lung cancer. Chest. 2005;128:308-316.
61. Hsieh R-K, Lim K-H, Kuo H-T, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest. 2005;128:317-321.
62. Nagai Y, Miyazawa H, Tanaka T, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res. 2005;65:7276-7286.
63. Tang X, Shigematsu H, Bekele BN, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005;65:7568-7572.
64. Haneda H, Sasaki H, Shimizu S, et al. Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. Lung Cancer. 2006;52:47-52.
65. Yoshida Y, Shibata T, Kokubu A, et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer. 2005;50:1-8.